Nepean Hospital

Kingswood NSW 2747

0 studies enrolling now · 11 studies all time

What they study most

Acute Coronary Syndrome, Acute Kidney Injury, Atrial Fibrillation, Colitis, Ulcerative, IgA Nephropathy, Immunoglobulin A Nephropathy, Liver Cirrhosis, Biliary, Liver Stiffness, Non Alcoholic Steatohepatitis (NASH), Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Prevention of Stroke or Systemic Embolism, Primary Biliary Cholangitis

Studies at this site

• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• Atrasentan in Patients With IgA Nephropathy — Running, not enrolling
• Pivotal Evaluation of Abdominal Neuromuscular Electrical Stimulation (VentFree) for Weaning From Mechanical Ventilation — Completed
• Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) — Completed
• A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness — Completed
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early
• Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial) — Completed
• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment — Stopped early
• A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment — Stopped early
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) — Stopped early